Recent advances in active specific cancer vaccine treatment for colorectal cancer

Current Pharmaceutical Biotechnology

Volumn 13, Issue 8, 2012, Pages 1439-1445

  Okuno, Kiyotaka ^a   Sugiura, Fumiaki ^a   Itoh, Kyogo ^b   Yoshida, Koji ^c   Tsunoda, Takuya ^c   Nakamura, Yusuke ^c  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Active specific cancer vaccine; Cancer specific peptide vaccine; Colorectal cancer (CRC); Personalized peptide vaccine

Indexed keywords

CANCER TESTIS ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; COMPLEMENTARY DNA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; FOLINATE CALCIUM; FOLINIC ACID; HLA A24 ANTIGEN; HLA ANTIGEN; IRINOTECAN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OXALIPLATIN; RECOMBINANT ANTIGEN; RECOMBINANT CARCINOEMBRYONIC ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT VASCULOTROPIN; RECOMBINANT VASCULOTROPIN RECEPTOR 1; RECOMBINANT VASCULOTROPIN RECEPTOR 2; TS 1; UFT; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VIRUS VECTOR;

ANTIGEN PRESENTING CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA MICROARRAY; DRUG DEGRADATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FOLLOW UP; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; HAZARD RATIO; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; INJECTION SITE REACTION; LYMPHOCYTIC INFILTRATION; MICROSATELLITE INSTABILITY; NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROGRESSION FREE SURVIVAL; RECEPTOR DOWN REGULATION; REVIEW; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM;

CANCER VACCINES; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY;

EID: 84862601930     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112800784998     Document Type: Review

References (38)

1. Boon, T. Tumor antigens recognized by cytolutic T lymphocytes: Present perspectives for specific immunotherapy. Int. J. Cancer, 1993, 54(2), 177-180.
2. Rosenberg, S.A. The development of new cancer therapies based on the molecular identification of cancer regression antigens. Cancer J. Sci. Am., 1995, 1(2): 89-100.
3. Jass, J. Lymphocytic infiltration and survival in rectal cancer. J. Clin. Pathol., 1986, 39(6), 585-589.
4. Ropponen, K.M.; Eskelinen, M.J.; Lipponen, P.K.; Alhava, E.; Kosma, V.M. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J. Pathol., 1997, 182(3), 318-324.
5. Nanni, O.; Volpi, A.; Frassineti, G.L.; de Paola, F.; Granato, A.M.; Dubini, A.; Zoli, W.; Scarpi, E.; Turci, D.; Oliverio, G.; Gambi, A.; Amadori, D. Role of biological markers in the clinical outcome of colon cancer. Br. J. Cancer., 2002, 87(8), 868-875.
6. Nielsen, H.J.; Hansen, U.; Christensen, I.J.; Reinert, C.M.; Brunner, N.; Moesgaard, F. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J. Pathol., 1999, 189(4), 487-495.
7. Roncucci, L.; Fante, R.; Losi, L.; Di Gregorio, C.; Micheli, A.; Benatti, P.; Madenis, N.; Ganazzi, D.; Cassinadri, M.T.; Lauriola, P.; Ponz de Leon, M. Survival for colon and rectal cancer in a population-based cancer registry. Eur. J. Cancer, 1996, 32A(2), 295-302.
8. Naito, Y.; Saito, K.; Shiiba, K.; Ohuchi, A.; Saigenji, K.; Nagura, H.; Ohtani, H. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res., 1998, 58(16), 3491-3494.
9. Funada, Y.; Noguchi, T.; Kikuchi, R.; Takeno, S.; Uchida, Y.; Gabbert, H.E. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol. Rep., 2003, 10(2), 309-313.
10. Watanabe, T., Wu, T.T.; Catalano, P.J; Ueki, T.; Satriano, R.; Haller, D.G.; Benson, A.B.; Hamilton, S.R. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med., 2001, 344(16), 1196-1206.
11. Liu, K.; Wang, C.; Chen, L.; Cheng, A.; Lin, D.; Wu, Y.; Yu, W.; Hung, Y.; Yang, H.; Juang, S.; Peng, J. Generation of carcinoembryonic antigen (CEA)-specific T cell responses in HLA-A0201 and HLA-A2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin. Cancer Res., 2004 10(8), 2645-2651.
12. Weihrauch, M.R.; Ansen, S.; Jurkiewicz, E.; Geisen, C.; Xia, Z.; Anderson, K.S.; Gracien, E.; Schmidt, M.; Wittig, B.; Diel, V.; Wolf, J.; Bohlen, H.; Nadler, L.M. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin. Cancer Res., 2005, 11(16), 5993-6001.
13. Kavanagh, B.; Ko, A.; Venook, A.; Margolin, K.; Zeh, H.; Lotze, M.; Schillinger, B.; Liu, W.; Lu, Y.; Mitsky, P.; Schilling, M.; Bercovici, N.; Loudovaris, M.; Guillermo, R.; Lee, S.M.; Bender, J.; Mills, B.; Fong, L. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J. Immunother., 2007, 30(7): 762-772.
14. Marshall, J.L.; Hawkins, M.J.; Tsang, K.Y.; Richmond, E.; Pedicano, J.E.; Zhu, M.Z.; Schlom, J. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol., 1999, 17(1), 332-337.
15. Marshall, J.L.; Gully, J.L.; Arlen, P.M., Beetham, P.K.; Tsang, K.; Slack, R.; Hodge, J.W.; Doren, S.; Grosenbach D.W.; Hwang, J.; Fox, E.; Odogwu, L.; Park, S.; Panicali, D.; Schlom, J. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol., 2005, 23(4), 720-731.
16. Rosenberg, S.A.; Yang, J.C.; Restifo, N.P. Cancer immunotherapy: moving beyond current vaccines. Nat. Med., 2004, 10(9), 909-915.
17. Itoh, K.; Yamada, A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci., 2006, 97(10), 970-976.
18. Sato, Y.; Maeda, Y.; Shomura, H.; Sasatomi, T.; Takahashi, M.; Une, Y.; Kondo, M.; Shinohara, T.; Hida, N.; Katagiri, K.; Sato, M.; Yamada, A.; Yamana, H.; Harada, M.; Itoh, K.; Todo, S. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br. J. Cancer., 2004, 90(7), 1334-1342.
19. Noguchi, M.; Itoh, K.; Suekane, S.; Morinaga, A.; Sukehiro, A.; Suetsugu, N.; Katagiri, K.; Yamada, A.; Noda, S. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate, 2004, 60(1), 32-45.
20. Miyagi, Y.; Imai, N.; Sasatomi, T.; Yamada, A.; Mine, T.; Katagiri, K.; Nakagawa, M.; Muto, A.; Okouchi, S.; Isomoto, H.; Shirouzu, K.; Yamana, H.; Itoh, K. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination of SART3 peptides. Clin. Cancer Res., 2001, 7(12), 3950-3962.
21. Sato, Y.; Fujiwara, T.; Mine, T.; Shomura, H.; Homma, S.; Maeda, Y.; Tokunaga, N.; Ikeda, Y.; Ishihara, Y.; Yamada, A.; Tanaka, N.; Itoh, K.; Harada, M.; Todo, S. Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci., 2007, 98(7), 1113-1119.
22. Hattori, T.; Mine, T.; Komatsu, N.; Yamada, A.; Itoh, K.; Shiozaki, H.; Okuno, K. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol. Immunother., 2009, 58(11), 1845-1854.
23. Ullenhag, G.J.; Frödin, J.E.; Jeddi-Tehrani, M.; Strigard, K.; Eriksson, E.; Samanci, A.; Choudhury, A.; Nilsson, B.; Rossmann, E.D.; Mosolits, S.; Mellstedt, H. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin. Cancer Res., 2004, 10(10), 3273-3328.
24. Rammensee, H.G.; Frige, T.; Stevanovic, S. MHC ligands and peptide motifs. Immunogenetics, 1995 41(4), 178-228.
25. Harada, M.; Gohara, R.; Matsueda, S.; Muto, A.; Oda, T.; Iwamoto, Y.; Itoh, K. In vivo evidence that peptide vaccination can induce HLA-DR-restricted CD4+ T cells reactive to a class I tumor peptide. J. Immunol., 2004, 172(4), 2659-2667.
26. Mine, T.; Sato, Y.; Noguchi, M.; Sasatomi, T.; Gouhara, R.; Tsuda, N.; Tanaka, S.; Shomura, H.; Katagiri, K.; Rikimaru, T.; Shichijo, S.; Kamura, T.; Hashimoto, T.; Shirouzu, K.; Yamada, A.; Todo, S.; Itoh, K.; Yamana, H. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin. Cancer Res., 2004, 10(3), 929-937.
27. Antony, P.A.; Piccirillo, C.A.; Akpinarli, A.; Finkelstein, S.E.; Speiss, P.J.; Surman, D.R.; Palmer, D.C.; Chan, C.C., Klebanoff, C.A.; Overwijk, W.W.; Rosenberg, S.A.; Restifo, N.P. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 2005, 174(5), 2591-2601.
28. Uchida, N.; Tsunoda, T.; Wada, S.; Furukawa, Y.; Nakamura, Y.; Tahara, H. Ring Finger protein 43 as a new target for cancer immunotherapy. Clin. Cancer Res., 2004, 10(24), 8577-8586.
29. Shimokawa, T.; Matsushima, S.; Tsunoda, T.; Tahara, H.; Nakamura, Y.; Furukawa, Y. Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target. Int. J. Oncol., 2006, 29(2), 381-386.
30. Correale, P.; del Vecchio, M. T.; Genova, G. D.; Savellini, G. G.; Placa, M.L.; Terrosi, C.; Vestri, M.; Urso, R.; Lemonnier, F.; Aquino, A.; Bonmassar, E.; Giorgi, G.; Francini, G.; Cusi, M.G. 5- fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J. Natl. Cancer Inst. 2005, 97(19), 1437-1445.
31. Correale, P.; Cusi, M.G.; Tsang, K.Y.; del Vecchio, M.T.; Marcili, S.; Placa, M.L.; Intrivici, C.; Aquino, A.; Micheli, L.; Nencini, C.; Ferrari, F.; Giorgi, G.; Bonmassar, E.; Francini, G. Chemoimmunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J. Clin. Oncol., 2005, 23(35), 8950-8958.
32. Janeway, C.A.; Sclomchik, M.J.; Travers, P.; Walport, M. Using the immune response to attack tumors. In: Immunobiology, 6th ed.; Janeway, C.A.; Sclomchik, M.J.; Travers, P.; Walport, M., Eds.; Garland Science: New York, 2004 pp.630-642.
33. Wada, S.; Tsunoda, T.; Baba, T.; Primus, F.J.; Kuwano, H.; Shibuya, M.; Tahara, H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res., 2005, 65(11), 4939-4946.
34. Nagorsen, D.; Thiel, E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin. Cancer Res., 2006, 12(10): 3064-3069.
35. Vermorken, J.B.; Claessen, A.M.; van Tinteren, H.; Gall, H.E.; Ezinga, R.; Meijer, S.; Scheper, R.J.; Meijer, C.J.; Bloemena, E.; Ransom, J.H.; Hanna, M.G. Jr.; Pinedo, H.M. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet, 1999, 353(9150), 345-350.
36. Harris, J.E.; Ryan, L.; Hoover, H.C., Jr.; Stuart, R.K.; Oken, M.M.; Benson, A.B. 3rd.; Mansour, E.; Haller, D.G.; Manola, J.; Hanna, M.G. Jr. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J. Clin. Oncol., 2000, 18(1): 148-157.
37. Chamoto, K.; Wakita, D.; Narita, Y. Zhang, Y.; Noguchi, D.; Ohnishi, H.; Iguchi, T.; Sakai, T.; Ikeda, H.; Nishimura, T. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class IInegative tumor tissue by T-helper type 1 cell therapy. Cancer Res., 2006, 66(3): 1809-1817.
38. Ohkuri, T.; Sato, M.; Abe, H.; Tsuji, K.; Yamagishi, Y.; Ikeda, H.; Matsubara, N.; Kitamura, H.; Nishimura, T. Identification of a novel NY-ESO-1 promiscuous helper epitope presented by multiple MHC class II molecules found frequently in the Japanese population. Cancer Sci., 2007, 98(7): 1092-1098.